



# BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

Thomas Gaisl <sup>1</sup>, Chris D. Turnbull<sup>2,3</sup>, Gerrit Weimann<sup>4</sup>, Sigrun Unger<sup>5</sup>, Rudolf Finger<sup>5</sup>, Charles Xing<sup>6</sup>, Peter A. Cistulli<sup>7,8</sup>, Sophie West<sup>9</sup>, Alan K.I. Chiang <sup>10</sup>, Danny J. Eckert <sup>11</sup>, John R. Stradling<sup>2,3</sup> and Malcolm Kohler<sup>1,12</sup>

<sup>1</sup>Sleep Disorders Center and Pulmonary Division, University Hospital Zurich, Zurich, Switzerland. <sup>2</sup>National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. <sup>3</sup>Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. <sup>4</sup>Clinical Experimentation, Pharma Research Center, Bayer Pharma, Wuppertal, Germany. <sup>5</sup>Clinical Operations, Pharma Research Center, Bayer Pharma, Wuppertal, Germany. <sup>6</sup>Global Development, Bayer Healthcare Company, Beijing, China. <sup>7</sup>Sleep Research Group, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. <sup>8</sup>Dept of Respiratory and Sleep Medicine, Centre for Sleep Health and Research, Royal North Shore Hospital, Sydney, Australia. <sup>9</sup>Newcastle Regional Sleep Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. <sup>10</sup>Neuroscience Research Australia (NeuRA), Sydney, Australia. <sup>11</sup>Adelaide Institute for Sleep Health, Flinders health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, Australia. <sup>12</sup>Zurich Center for Interdisciplinary Sleep Research, University of Zurich, Zurich, Switzerland.

Corresponding author: Malcolm Kohler ([malcolm.kohler@usz.ch](mailto:malcolm.kohler@usz.ch))



Shareable abstract (@ERSpublications)

**BAY 2253651 is a nasally applied genioglossus muscle activator via pharyngeal mucosal receptor stimulation (potassium channel blocker) aimed to treat obstructive sleep apnoea. Although well-tolerated and safe, there was no significant therapeutic effect.** <https://bit.ly/3zDbyia>

**Cite this article as:** Gaisl T, Turnbull CD, Weimann G, *et al.* BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN). *Eur Respir J* 2021; 58: 2101937 [DOI: 10.1183/13993003.01937-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2021.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 2 July 2021  
Accepted: 23 Aug 2021

*To the Editor:*

For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approved [1–3]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.

